Table 2. Tumor response in the study patients (n = 50).
| No. of patients (%) | ||
|---|---|---|
| Primary site | Overall | |
| CR | 5 (10) | 1 (2) |
| PR | 35 (70) | 21 (42) |
| SD | 4 (8) | 11 (22) |
| PD | 0 (0) | 12 (24) |
| Not evaluable | 6 (12) | 5 (10) |
| Response (CR + PR) | 40 (80) | 22 (44) |
| Disease control (CR + PR + SD) | 44 (88) | 33 (66) |